These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. Tropea TF; Xie SX; Rick J; Chahine LM; Dahodwala N; Doshi J; Davatzikos C; Shaw LM; Van Deerlin V; Trojanowski JQ; Weintraub D; Chen-Plotkin AS Mov Disord; 2018 Feb; 33(2):289-297. PubMed ID: 29168904 [TBL] [Abstract][Full Text] [Related]
44. Assessment of cognitive-driven activity of daily living impairment in non-demented Parkinson's patients. Becker S; Bäumer A; Maetzler W; Nussbaum S; Timmers M; Van Nueten L; Salvadore G; Zaunbrecher D; Roeben B; Brockmann K; Streffer J; Berg D; Liepelt-Scarfone I J Neuropsychol; 2020 Mar; 14(1):69-84. PubMed ID: 30320954 [TBL] [Abstract][Full Text] [Related]
45. Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition. Phannarus H; Muangpaisan W; Siritipakorn P; Chotinaiwattarakul W Psychogeriatrics; 2020 Jan; 20(1):20-27. PubMed ID: 30912230 [TBL] [Abstract][Full Text] [Related]
46. Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease. Melzer TR; Stark MR; Keenan RJ; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Grenfell S; Horne KL; Young BN; Pascoe MJ; Almuqbel MM; Wang J; Marsh SH; Miller DH; Dalrymple-Alford JC; Anderson TJ Front Neurol; 2019; 10():391. PubMed ID: 31105633 [TBL] [Abstract][Full Text] [Related]
47. NREM sleep arousal-related disorders reflect cognitive impairment in Parkinson's disease. Terzaghi M; Minafra B; Zangaglia R; Picascia M; Pozzi N; Cremascoli R; Arnaldi D; Versino M; Sinforiani E; Rustioni V; Pacchetti C; Manni R Sleep Med; 2020 Nov; 75():491-496. PubMed ID: 33011475 [TBL] [Abstract][Full Text] [Related]
48. Changes in Motor, Cognitive, and Behavioral Symptoms in Parkinson's Disease and Mild Cognitive Impairment During the COVID-19 Lockdown. Baschi R; Luca A; Nicoletti A; Caccamo M; Cicero CE; D'Agate C; Di Giorgi L; La Bianca G; Lo Castro T; Zappia M; Monastero R Front Psychiatry; 2020; 11():590134. PubMed ID: 33381057 [No Abstract] [Full Text] [Related]
49. Conversion to MCI and dementia in Parkinson's disease: a systematic review and meta-analysis. Saredakis D; Collins-Praino LE; Gutteridge DS; Stephan BCM; Keage HAD Parkinsonism Relat Disord; 2019 Aug; 65():20-31. PubMed ID: 31109727 [TBL] [Abstract][Full Text] [Related]
50. Greater intraindividual variability in neuropsychological performance predicts cognitive impairment in de novo Parkinson's disease. Jones JD; Burroughs M; Apodaca M; Bunch J Neuropsychology; 2020 Jan; 34(1):24-30. PubMed ID: 31219297 [TBL] [Abstract][Full Text] [Related]
51. Changes of brain structure in Parkinson's disease patients with mild cognitive impairment analyzed via VBM technology. Gao Y; Nie K; Huang B; Mei M; Guo M; Xie S; Huang Z; Wang L; Zhao J; Zhang Y; Wang L Neurosci Lett; 2017 Sep; 658():121-132. PubMed ID: 28823894 [TBL] [Abstract][Full Text] [Related]
52. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment. Gasca-Salas C; Clavero P; García-García D; Obeso JA; Rodríguez-Oroz MC Hum Brain Mapp; 2016 Mar; 37(3):968-77. PubMed ID: 26663702 [TBL] [Abstract][Full Text] [Related]
53. Mild cognitive impairment in patients with Parkinson's disease is associated with increased cortical degeneration. Hanganu A; Bedetti C; Jubault T; Gagnon JF; Mejia-Constain B; Degroot C; Lafontaine AL; Chouinard S; Monchi O Mov Disord; 2013 Sep; 28(10):1360-9. PubMed ID: 23801590 [TBL] [Abstract][Full Text] [Related]
54. Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease. Kandiah N; Zainal NH; Narasimhalu K; Chander RJ; Ng A; Mak E; Au WL; Sitoh YY; Nadkarni N; Tan LC Parkinsonism Relat Disord; 2014 Nov; 20(11):1203-8. PubMed ID: 25258331 [TBL] [Abstract][Full Text] [Related]
55. Longitudinal study of cognitive and cerebral metabolic changes in Parkinson's disease. Baba T; Hosokai Y; Nishio Y; Kikuchi A; Hirayama K; Suzuki K; Hasegawa T; Aoki M; Takeda A; Mori E J Neurol Sci; 2017 Jan; 372():288-293. PubMed ID: 28017230 [TBL] [Abstract][Full Text] [Related]
56. Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment. Simon-Gozalbo A; Rodriguez-Blazquez C; Forjaz MJ; Martinez-Martin P Front Neurol; 2020; 11():731. PubMed ID: 32849203 [No Abstract] [Full Text] [Related]
57. A parsimonious scoring and normative calculator for the Parkinson's disease mild cognitive impairment battery. Bezdicek O; Sulc Z; Nikolai T; Stepankova H; Kopecek M; Jech R; Růžička E Clin Neuropsychol; 2017; 31(6-7):1231-1247. PubMed ID: 28276860 [TBL] [Abstract][Full Text] [Related]
58. Education-corrected CERAD identifies MCI and dementia in Parkinson's disease. Karrasch M; Laatu S; Ellfolk U; Marttila R; Martikainen K Acta Neurol Scand; 2015 Apr; 131(4):219-24. PubMed ID: 25273524 [TBL] [Abstract][Full Text] [Related]
59. Response to "Parkinson's disease mild cognitive impairment classifications and neurobehavioral symptoms". Horne KL; Myall DJ; MacAskill MR; Anderson TJ; Dalrymple-Alford JC Int Psychogeriatr; 2018 Sep; 30(9):1415. PubMed ID: 29606167 [TBL] [Abstract][Full Text] [Related]
60. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease. Kandiah N; Zhang A; Cenina AR; Au WL; Nadkarni N; Tan LC Parkinsonism Relat Disord; 2014 Nov; 20(11):1145-8. PubMed ID: 25176439 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]